Day: November 7, 2024

Company to Highlight Industry-Leading Technologies in a Series of Reference Designs and Demonstrations Focused on AI, Alternative Energy, Automation, E-Mobility, and More MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) — Vishay Intertechnology, Inc. (NYSE: VSH) today announced that at electronica 2024, the company will be exhibiting its broad portfolio of passive and semiconductor solutions, and discussing their pivotal role in shaping a sustainable future through the all-electric society. Vishay experts will be on hand to dive into cutting-edge developments in automation, AI, e-mobility, and smart and alternative energy technologies. In hall C4, booth 478, Vishay will be showcasing its differentiated products and solutions in a range of applications and use cases, including AI, alternative energy, energy storage systems (ESS), ADAS,...

— Metastatic non-small cell lung cancer (NSCLC) patients treated in the first line setting with IO102-IO103 in combination with Keytruda® demonstrated promising activity with an overall response rate of 55% unconfirmed/48% confirmed, disease control rate of 81%, and approximately 50% of patients without disease progression at 12 months; median duration of response not reached — — Safety profile consistent with prior studies with the combination, showing no unexpected toxicities compared to anti-PD1 monotherapy, and low-grade transient injection site reactions as the most common treatment related adverse event — — The data from this NSCLC cohort combined with the recent positive squamous cell carcinoma of the head and neck (SCCHN) cohort data presented at ESMO 2024 and previously reported positive Phase 1/2...

BDC-4182 demonstrated compelling anti-tumor activity and an acceptable safety profile in preclinical studies BDC-4182 outperformed cytotoxic claudin 18.2 ADCs in syngeneic model Learnings from BDC-1001 data suggest Boltbody™ ISACs with enhanced immune activation could offer greater efficacy, warranting further testing REDWOOD CITY, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) — Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today presented updated preclinical data for BDC-4182, a next-generation Boltbody™ ISAC clinical candidate targeting claudin 18.2, and provided key learnings from its Phase 1 dose-escalation trial of BDC-1001 at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held in Houston,...

IMNN-001 immunotherapy plus standard-of-care chemotherapy resulted in 35% improvement in overall survival and 25% improvement in progression-free survival versus standard-of-care alone Treatment was generally well tolerated, with no reports of cytokine release syndrome or any other serious immune related adverse events Company plans to initiate Phase 3 pivotal trial of IMNN-001 in Q1 2025 LAWRENCEVILLE, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) — IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced the presentation of new clinical data from the recently completed Phase 2 OVATION 2 Study of IMNN-001, its investigational interleukin-12 (IL-12) immunotherapy for the treatment of advanced ovarian cancer based on the company’s proprietary TheraPlas® technology....

Phase 1 TRAVERSE Trial Demonstrated a Single Infusion of ALLO-316 Can Yield an Overall Response Rate of 50% and Confirmed Response Rate of 33% in Patients with CD70 Tumor Proportion Score (TPS) of Greater than 50% TRAVERSE Trial Highlights the Ability of CD70 Dagger® Technology to Promote Robust Expansion and Persistence of ALLO-316 with Standard Lymphodepletion, Validating its Potential as the Next Generation Allogeneic Platform  ALLO-316 Demonstrated a Manageable Safety Profile; Newly Implemented Diagnostic and Management Algorithm Appears Highly Effective in Abating IEC-HS While Preserving CAR T Efficacy Data from the TRAVERSE Trial Supported the FDA’s Recent RMAT Designation for ALLO-316 as a Potential Treatment for Advanced or Metastatic RCCSOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) — Allogene Therapeutics,...

AgenT-797 Combination with Checkpoint Inhibitors and Bispecific Engagers Expands Anti-Cancer Benefit PRAME-TCR iNKT Overcomes Challenges from Conventional TCR-T Cells in Solid Cancers NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced data from two poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting in Houston, Texas. The presentations showcased new data from MiNK’s iNKT cell therapy programs, agenT-797 and PRAME-TCR. “The data we presented at SITC reflect the potential of iNKT cell therapies to offer meaningful...

TORONTO, Nov. 07, 2024 (GLOBE NEWSWIRE) — NEO Battery Materials Ltd.(TSXV: NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, is highly pleased to announce the signing of a Memorandum of Understanding (“MOU”) with Linde Korea Co., Ltd. (“Linde”), an affiliate of the leading industrial gases and engineering company, on November 6, 2024, to collaborate on the scale-up of NEO’s silicon anode manufacturing for lithium-ion batteries. There are no material terms or considerations regarding this MOU. Under the MOU, Linde, NEO, and NBM Korea Co. (“NBMK”) will collaborate to incorporate and optimize Linde’s industrial gases, specifically nitrogen and argon, as critical inert gases in NEO’s silicon anode manufacturing process. These gases have a significant role...

Press ReleaseVELIZY-VILLACOUBLAY, France — November 7, 2024 Declaration of the number of outstanding shares and voting rights as of October 31, 2024 Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) today announced below the total number of its outstanding shares and voting rights as of October 31, 2024, according to articles 223-16 and 221-3 of the General Regulation of the Autorité des marchés financiers. Number of outstanding shares: 1,339,460,603 Number of voting rights*: 2,013,203,694 *The total number of voting rights is calculated on the basis of the total number of outstanding shares, even if the voting rights attached thereto are suspended, pursuant to Article 223-11 of the General Regulation of the Autorité des marchés financiers relating to the method for calculating the percentages of holdings in shares and in voting...

New York, NY, Nov. 07, 2024 (GLOBE NEWSWIRE) — GSR III Acquisition Corp. (NASDAQ: GSRT) (“GSRT” or the “Company”) announced today the pricing of its initial public offering of 20,000,000 units at a price of $10.00 per unit, for aggregate gross proceeds of $200,000,000. The units will be listed on the Nasdaq Global Market LLC (“Nasdaq”) and begin trading today under the ticker symbol “GSRTU.” Each unit consists of one of the Company’s Class A ordinary shares (the “Class A Ordinary Shares”) and one-seventh (1/7th) of one right (the “Rights”), with each whole right entitling the holder thereof to receive one Class A Ordinary Share upon the consummation of an initial business combination. No fractional rights will be issued upon separation of the units and only whole rights will trade. Once the securities comprising the units begin...